PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
WKEY vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between WKEY and RXRX is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

WKEY vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in WISeKey International Holding AG (WKEY) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

0.00%100.00%200.00%300.00%400.00%500.00%SeptemberOctoberNovemberDecember2025February
170.21%
42.63%
WKEY
RXRX

Key characteristics

Sharpe Ratio

WKEY:

0.63

RXRX:

-0.15

Sortino Ratio

WKEY:

2.95

RXRX:

0.41

Omega Ratio

WKEY:

1.38

RXRX:

1.05

Calmar Ratio

WKEY:

1.29

RXRX:

-0.15

Martin Ratio

WKEY:

4.36

RXRX:

-0.25

Ulcer Index

WKEY:

28.78%

RXRX:

49.49%

Daily Std Dev

WKEY:

198.67%

RXRX:

86.37%

Max Drawdown

WKEY:

-98.00%

RXRX:

-88.97%

Current Drawdown

WKEY:

-91.49%

RXRX:

-73.70%

Fundamentals

Market Cap

WKEY:

$16.31M

RXRX:

$4.25B

EPS

WKEY:

-$2.51

RXRX:

-$1.54

Total Revenue (TTM)

WKEY:

$20.83M

RXRX:

$54.29M

Gross Profit (TTM)

WKEY:

$12.58M

RXRX:

$14.55M

EBITDA (TTM)

WKEY:

-$20.88M

RXRX:

-$262.33M

Returns By Period

In the year-to-date period, WKEY achieves a -33.85% return, which is significantly lower than RXRX's 60.80% return.


WKEY

YTD

-33.85%

1M

-18.61%

6M

170.43%

1Y

123.51%

5Y*

-26.22%

10Y*

N/A

RXRX

YTD

60.80%

1M

66.46%

6M

42.65%

1Y

-13.66%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

WKEY vs. RXRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

WKEY
The Risk-Adjusted Performance Rank of WKEY is 8282
Overall Rank
The Sharpe Ratio Rank of WKEY is 6868
Sharpe Ratio Rank
The Sortino Ratio Rank of WKEY is 9191
Sortino Ratio Rank
The Omega Ratio Rank of WKEY is 9090
Omega Ratio Rank
The Calmar Ratio Rank of WKEY is 8383
Calmar Ratio Rank
The Martin Ratio Rank of WKEY is 7979
Martin Ratio Rank

RXRX
The Risk-Adjusted Performance Rank of RXRX is 4040
Overall Rank
The Sharpe Ratio Rank of RXRX is 3838
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 4343
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 4141
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 3737
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 4141
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

WKEY vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for WISeKey International Holding AG (WKEY) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for WKEY, currently valued at 0.63, compared to the broader market-2.000.002.000.63-0.15
The chart of Sortino ratio for WKEY, currently valued at 2.95, compared to the broader market-4.00-2.000.002.004.006.002.950.41
The chart of Omega ratio for WKEY, currently valued at 1.38, compared to the broader market0.501.001.502.001.381.05
The chart of Calmar ratio for WKEY, currently valued at 1.32, compared to the broader market0.002.004.006.001.32-0.15
The chart of Martin ratio for WKEY, currently valued at 4.36, compared to the broader market0.0010.0020.0030.004.36-0.25
WKEY
RXRX

The current WKEY Sharpe Ratio is 0.63, which is higher than the RXRX Sharpe Ratio of -0.15. The chart below compares the historical Sharpe Ratios of WKEY and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
0.63
-0.15
WKEY
RXRX

Dividends

WKEY vs. RXRX - Dividend Comparison

Neither WKEY nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

WKEY vs. RXRX - Drawdown Comparison

The maximum WKEY drawdown since its inception was -98.00%, which is greater than RXRX's maximum drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for WKEY and RXRX. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%SeptemberOctoberNovemberDecember2025February
-83.04%
-73.70%
WKEY
RXRX

Volatility

WKEY vs. RXRX - Volatility Comparison

WISeKey International Holding AG (WKEY) has a higher volatility of 39.05% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 29.14%. This indicates that WKEY's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


20.00%40.00%60.00%80.00%100.00%120.00%140.00%SeptemberOctoberNovemberDecember2025February
39.05%
29.14%
WKEY
RXRX

Financials

WKEY vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between WISeKey International Holding AG and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab